Can low-dose aspirin be given after percutaneous coronary intervention (PCI)?

Yes, aspirin should absolutely be given after angioplasty (PCI) and continued indefinitely.

After PCI, aspirin must be continued indefinitely at a low dose of 75-100 mg (81 mg) daily 1, 2, 3, 4. This is a Class I recommendation with Level of Evidence A from multiple ACC/AHA/SCAI guidelines, representing the highest strength of recommendation based on robust clinical evidence.

Dosing Strategy

The optimal maintenance dose is 75-100 mg (81 mg) daily, NOT higher doses:

• Low-dose aspirin (75-100 mg daily) is preferred over higher maintenance doses (Class IIa, Level of Evidence B) 1, 2, 1, 4
• The most recent 2025 ACC/AHA guidelines specifically recommend 75-100 mg daily for maintenance therapy, emphasizing this exceeds the minimal effective dose for platelet thromboxane A suppression while allowing for interindividual variability 4

Before the procedure:

• If already on aspirin: take 81-325 mg before PCI 2
• If not on aspirin: give nonenteric 325 mg (chewed when possible for faster onset) before PCI 2, 4

Why Low-Dose is Superior

The evidence strongly favors low-dose aspirin post-PCI:

• High-dose aspirin (>200 mg daily) increases bleeding risk without additional ischemic benefit 5, 6
• In the HORIZONS-AMI trial, high-dose aspirin was an independent predictor of major bleeding (HR 2.80,95% CI 1.31-5.99, p=0.008) without reducing ischemic events 5
• The PCI-CURE study showed major bleeding rates of 3.9% with high-dose vs 1.9% with low-dose aspirin, with similar efficacy for preventing cardiovascular death, MI, or stroke 6
• A 2016 meta-analysis of 25,083 patients found high-dose aspirin significantly increased major adverse cardiac events (OR 1.20, p=0.03) and TIMI minor bleeding (OR 1.22, p=0.03) compared to low-dose 7

Duration and Combination Therapy

Aspirin is given indefinitely as part of dual antiplatelet therapy (DAPT):

• Combined with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) for a specified duration depending on stent type and clinical presentation 1, 2
• For ACS with stent (BMS or DES): DAPT for at least 12 months 1, 2
• For non-ACS with DES: DAPT for at least 12 months if not high bleeding risk 1, 2
• For non-ACS with BMS: DAPT minimum 1 month, ideally up to 12 months 1, 2

After DAPT discontinuation, aspirin continues indefinitely alone 1, 3, 1

Important Caveats

Bleeding risk considerations:

• Patients with prior GI bleeding should receive proton pump inhibitors (PPIs) with DAPT (Class I, Level C) 1, 2
• If bleeding risk outweighs benefit, earlier P2Y12 inhibitor discontinuation is reasonable, but aspirin continues 1, 2, 1

Special populations:

• When using ticagrelor, aspirin doses ≤100 mg daily should always be used based on PLATO trial post-hoc analysis 4
• Recent 2025 data from STOPDAPT-3 suggests aspirin-free strategies (P2Y12 inhibitor monotherapy) may be considered in non-ACS high bleeding risk patients, but showed concerning signals for increased MI in ACS patients 8

Patient counseling is mandatory:

• Patients must understand the importance of DAPT compliance and should not discontinue therapy without discussing with their cardiologist (Class I, Level C) 1, 2

Bottom Line Algorithm

1. Give aspirin loading before/during PCI (81-325 mg if already on aspirin; 325 mg nonenteric if not)
2. Start DAPT immediately (aspirin + P2Y12 inhibitor)
3. Transition to low-dose aspirin 75-100 mg (81 mg) daily for maintenance
4. Continue DAPT for appropriate duration based on stent type and clinical presentation
5. After DAPT period ends, continue aspirin 81 mg daily indefinitely
6. Add PPI if prior GI bleeding or multiple bleeding risk factors

The evidence is unequivocal: aspirin is essential post-PCI, but the dose matters—lower is better for safety without compromising efficacy.